Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.
暂无分享,去创建一个
S. Kochanek | J. Reimann | R. Schirmbeck | F. Kreppel | S. Corjon | Andreas Wortmann | T. Engler | Sabine Vöhringer | Sabine Vöhringer
[1] N. Letvin,et al. Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors , 2007, Journal of Virology.
[2] J. Mascola,et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.
[3] A. Stryhn,et al. Alteration of epitope recognition pattern in Ag85B and ESAT‐6 has a profound influence on vaccine‐induced protection against Mycobacterium tuberculosis , 2006, European journal of immunology.
[4] A. Parker,et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.
[5] K. Mansfield,et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.
[6] K. Ulbrich,et al. Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells , 2006, Gene Therapy.
[7] D. Collen,et al. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. , 2005, Human gene therapy.
[8] S. Kochanek,et al. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] A. Gaggar,et al. Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.
[10] B. Walker,et al. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.
[11] P. Krebs,et al. Rapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus1 , 2005, The Journal of Immunology.
[12] A. Beaudet,et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile , 2005, Gene Therapy.
[13] Hildegund C.J. Ertl,et al. Adenoviruses as vaccine vectors , 2004, Molecular Therapy.
[14] D. Moon,et al. Imaging of human sodium-iodide symporter gene expression mediated by recombinant adenovirus in skeletal muscle of living rats , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[15] S. Kostense,et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.
[16] S. Kostense,et al. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.
[17] R. K. Evans,et al. Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.
[18] D. Collen,et al. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. , 2003, Blood.
[19] James M. Wilson,et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. , 2002, Human gene therapy.
[20] S. Ylä-Herttuala,et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ , 2002, The journal of gene medicine.
[21] S. Kochanek,et al. A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. , 2002, Human gene therapy.
[22] James M. Wilson,et al. “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.
[23] S. Kochanek,et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. , 2000, Human gene therapy.
[24] J. Wilson,et al. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.
[25] F. Chisari,et al. Ongoing Murine T1 or T2 Immune Responses to the Hepatitis B Surface Antigen Are Excluded from the Liver that Expresses Transgene-Encoded Hepatitis B Surface Antigen1 , 2000, The Journal of Immunology.
[26] D. Metz,et al. The liver as a site of T‐cell apoptosis: graveyard, or killing field? , 2000, Immunological reviews.
[27] R. Offringa,et al. Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset , 1999, Journal of Virology.
[28] H. Romanczuk,et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. , 1999, Human gene therapy.
[29] A. Juedes,et al. Selective retention of activated CD8+ T cells by the normal liver. , 1999, Journal of immunology.
[30] Alan E. Smith,et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.
[31] T. Libermann,et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.
[32] James M. Wilson,et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.
[33] M. Barry,et al. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[34] S. Gurunathan,et al. DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.